Search Results
Your search for ,foR matches 32434 pages
Showing 11751 - 11800Neoadjuvant Atezolizumab Plus Chemotherapy for Resectable NSCLC
In a phase II study reported in The Lancet Oncology, Shu et al found that neoadjuvant treatment with atezolizumab plus nab-paclitaxel/carboplatin produced a major pathologic response in 57% of patients and a complete pathologic response in 33% of patients with resectable, predominantly stage IIIA...
Lessons Learned on Rotation at COVID-19 Inpatient Service at New York City Hospital
AS I WRITE TO YOU, I am happy to report I have just completed a 7-day rotation at the COVID-19 inpatient service at my hospital in New York City! Overall, it was a positive experience, despite the occasional sad and scary moments. I left the service feeling uplifted and fulfilled. I am glad to have ...
Germline Genetic Variants in ATM and Lung Cancer Susceptibility
An international consortium of researchers has identified a mutation involved in a person’s susceptibility to lung cancer. This variant could help identify certain populations at greater risk for lung cancer, according to results reported by Ji et al in Nature Communications. ATM Variant Their...
Antihistamines May Improve Survival Among Patients With Malignant Melanoma
In a research letter published by Fritz et al in the journal Allergy, researchers reported that the common allergy medications desloratadine and loratadine may be associated with improved survival in patients with malignant melanoma. “Previous studies have shown that the same antihistamines have...
Do Marital Status and Race Affect the Treatment of Esophageal Cancer?
A study using data from the Michigan state cancer registry, reported in JCO Oncology Practice by Paniagua Cruz et al, found that a higher proportion of white vs black patients with esophageal cancer were married; that single patients were less likely to receive esophagectomy and chemotherapy; and...
COVID-19 Infection in Pediatric Patients With Cancer
In a study reported in a research letter in JAMA Oncology, Boulad et al found a low rate of COVID-19 morbidity among infected pediatric patients with cancer seen in the Memorial Sloan Kettering Cancer Center pediatric program, as well as a low rate of infection in patients without COVID-19...
Online Guide Offers Tips for Communicating With Patients During the COVID-19 Pandemic
A NEW ONLINE GUIDE provides tips to help oncology and other clinicians navigate the difficult and distressing communications with patients that have arisen during the COVID-19 pandemic. Anthony Back, MD, a medical oncologist and palliative medicine specialist at the University of Washington and...
New ASCO Guideline Addresses Head/Neck Squamous Cell Carcinoma of Unknown Primary
ASCO has released a new clinical guideline titled, “Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline.”1 The guideline, promulgated by an international expert panel, is intended to “provide evidence-based recommendations to practicing...
Atezolizumab Plus Bevacizumab vs Sorafenib in Treatment-Naive Patients With Unresectable Hepatocellular Carcinoma
As reported in The New England Journal of Medicine by Richard S. Finn, MD, and colleagues, the phase III IMbrave150 trial has shown that anti–programmed cell death ligand 1 (PD-L1) plus anti-VEGF therapy with atezolizumab plus bevacizumab improved progression-free and overall survival vs sorafenib ...
ASCO Special Report Provides Guidance to Oncology Practices on Resuming Cancer Care During the COVID-19 Pandemic
ASCO has released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic, which provides detailed guidance to oncology practices on the immediate and short-term steps that could be taken to help protect the safety of patients and health-care staff before resuming more ...
Do Men Treated With ADT for Prostate Cancer Have a Lower Risk of Acquiring COVID-19?
A study of 4,532 men in the Veneto region of Italy has found that those who were being treated for prostate cancer with androgen-deprivation therapies (ADT) were less likely to develop COVID-19, and if they were infected, their disease tended to be less severe. This research was published by...
FDA Approves Olaparib for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
On May 19, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who have had disease progression...
Low-Intensity Surveillance as an Option for Some Patients With Non–Muscle Invasive Bladder Cancer
Low-intensity cystoscopic surveillance may be a viable option for patients with high-risk, non–muscle invasive bladder cancer, according to data from a paper presented to the media during a special session moderated by the American Urological Association (AUA) on May 15. The research was also...
Can Pain After Prostatectomy or Nephrectomy Be Managed Without Opioids?
The use of opioids continues to be major issue facing patients with cancer in the United States. Most patients undergoing prostate and kidney removal may be managed effectively without opioids during the postoperative period, according to new data from researchers in Pittsburgh highlighted during a ...
Overall Survival With the Addition of ADT or Brachytherapy Boost to External-Beam Radiotherapy in Patients With Localized Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Jackson et al found that the common practice of omitting androgen-deprivation therapy (ADT) from treatment with external-beam radiotherapy (EBRT) plus a brachytherapy boost (BT) may be associated with poorer overall survival in men with...
NIH-Led ACTIV Program for the Development of COVID-19 Vaccines
In an article published in Science, Lawrence Corey, MD; John R. Mascola, MD; Anthony S. Fauci, MD; and Francis S. Collins, MD, PhD, describe the composition and aims of the National Institutes of Health (NIH)-led Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership....
Detecting Relapse in Patients With Lymphoma in First Remission: Value of Surveillance Laboratory Testing
In a single-institution retrospective study reported in JCO Oncology Practice, Lynch et al found that routine laboratory surveillance testing had limited value in detecting relapse in patients with classical Hodgkin lymphoma in first remission. Study Details The study involved 235 patients at...
FDA Approves Atezolizumab for the First-Line Treatment of Patients With Metastatic NSCLC and High PD-L1 Expression
On May 18, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high programmed cell death ligand 1 (PD-L1) expression (PD-L1 stained ≥ 50% of tumor cells or...
Physical Activity and Neurocognitive Function in Adult Survivors of Childhood Cancers
In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Barlow-Krelina et al found that consistent physical activity vs consistent inactivity was associated with reduced neurocognitive problems and greater improvement in neurocognitive domains during long-term...
FDA Pipeline: Two Breakthrough Therapy Designations for Fam-Trastuzumab Deruxtecan-nxki, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designations for an antibody-drug conjugate in the treatment of gastric and lung cancers. The Agency has also issued Orphan Drug designations for agents being investigated in chronic myeloid...
Cancer Care at Tata Memorial Centre During the COVID-19 Pandemic
In correspondence published in The New England Journal of Medicine, two practitioners from Tata Memorial Centre, India’s largest cancer center, describe measures taken to continue providing cancer care during the COVID-19 pandemic in India. As related by the authors, scaling back of operations at...
FDA Approves Rucaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib (Rubraca) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor–directed therapy...
FDA Approves Ripretinib for Previously Treated Patients With Advanced Gastrointestinal Stromal Tumor
On May 15, the U.S. Food and Drug Administration (FDA) approved ripretinib (Qinlock) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. INVICTUS Trial Efficacy was...
FDA Approves Nivolumab/Ipilimumab for First-Line Treatment of Patients With Metastatic NSCLC and PD-L1 Tumor Expression ≥ 1%
On May 15, 2020, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express programmed cell death ligand 1 (PD-L1) at ≥ 1%, as...
Selected Poster Presentations on Cancer Therapeutics and More
Although the live 2020 National Comprehensive Cancer Network (NCCN) Annual Conference was canceled, more than 100 posters scheduled for presentation are now available online, as part of the NCCN 2020 Virtual Annual Conference. The ASCO Post has summarized some of the clinical trial updates we found ...
10 Changes I Will Make in My Oncology Practice as a Result of COVID-19
As a result of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or COVID-19) global pandemic, medicine—including oncology practice—will never be the same. We find ourselves in a time of emergency medicine for all specialties, technologic innovation (eg, more prevalent use of...
Study Finds a High Rate of Intra- and Postoperative Conversions to Total Thyroidectomy
The overall risk of needing a total thyroidectomy was found to be 19.4% for patients undergoing lobectomy for indeterminate and high-risk thyroid nodule, according to a report published by Moore et al in the World Journal of Surgery. The study also found that 21% and 26.5% of patients originally...
FDA Approves Pomalidomide for Kaposi Sarcoma
On May 14, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of pomalidomide (Pomalyst) to include treating adult patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failure of highly active antiretroviral therapy and those with Kaposi...
Does Text Messaging Support Adherence to Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer?
In the SWOG S1105 trial reported in the Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, and colleagues found that a text message intervention did not reduce the rate of early discontinuation of adjuvant aromatase inhibitor therapy in postmenopausal women with early-stage breast cancer....
Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.
New Study Shows Patients With Cancer Had Lower Rates of Detected COVID-19 Antibodies vs Health-Care Workers
Results from an analysis involving both patients with cancer and health-care workers at Centre Léon Bérard in Lyon, France, showed that patients with cancer had a significantly lower detection rate of SARS-CoV-2 antibodies 15 days or more after COVID-19 symptoms and a positive reverse transcription ...
Combining Pembrolizumab With IL-12 Electroporation May Improve Clinical Response in Patients With Immunologically 'Cold' Melanoma
Patients with non–immune-infiltrated “cold” tumors have low frequencies of intratumoral tumor-reactive, checkpoint-positive cytotoxic lymphocytes, making them less responsive to checkpoint blockage than patients with immune-infiltrated “hot” tumors. A phase II study by Alain P. Algazi, MD, and...
First-Line Concomitant and Sequential Nivolumab/AVD for Early-Stage Unfavorable Classical Hodgkin Lymphoma
In a phase II German Hodgkin Study Group trial (NIVAHL) reported in JAMA Oncology, Bröckelmann et al found that both concomitant and sequential nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) regimens showed efficacy in first-line treatment of early-stage unfavorable classical...
Effectiveness of Different Severity Thresholds for Chemotherapy-Related Symptom Alerts
In a study reported in JCO Oncology Practice, Shi et al found that use of higher-than-currently-recommended severity thresholds for symptom alerts for patients receiving outpatient chemotherapy would result in failure to identify and treat many patients requiring clinical intervention for ...
Quitting Smoking at Any Point Improves Lung Cancer Survival, Study Finds
People who quit smoking at any time—even 2 years before a lung cancer diagnosis—improve their chances of survival after being diagnosed with the disease, according to the results of a large international study presented by Fares et al in a press briefing in advance of the ASCO20 Virtual Scientific...
Edward B. Garon, MD, on NSCLC: Long-Term Use of Pemetrexed Plus Platinum With Pembrolizumab
Edward B. Garon, MD, of the University of California, Los Angeles David Geffen School of Medicine, discusses KEYNOTE-189 trial findings that showed adding pembrolizumab to pemetrexed plus platinum—which previously was found to improve overall and progression-free survival—is also safe and has...
Nickolas Papadopoulos, PhD, on Liquid Biopsy to Screen for Multiple Cancer Types
Nickolas Papadopoulos, PhD, of Johns Hopkins Medicine, discusses a first-of-its-kind prospective study that evaluated a screening blood test in more than 10,000 older women with no history of cancer. The test, called DETECT-A, identified 10 different cancer types, 65% of which were early-stage...
Videoconference Intervention Can Reduce Levels of Anxiety and Distress Among Distance Caregivers
According to the National Alliance for Caregiving, the number of adult individuals in the United States providing care for patients with cancer ranges between 2.8 million and 6.1 million. Caregivers for patients with cancer who live more than 1 hour away report having higher levels of anxiety and...
Expert Point of View: William Dale, MD, PhD
"We have known for a long time, based on good evidence, that geriatric assessment is good at accurately identifying patients at high risk for chemotherapy-induced toxicity, surgical complications, and increased hospitalizations. This study adds an intervention component based on the geriatric...
Geriatrician Assessment and Integrated Care May Help Older Patients as Well as the Health-Care System
A full geriatric assessment and geriatrician-led multidisciplinary care improved the quality of life of patients aged 70 and older undergoing chemotherapy, targeted therapy, or immunotherapy, according to results of a prospective, randomized, controlled, open-label trial, reported in a press...
Expert Point of View: Don S. Dizon, MD, FACP, FASCO
Commenting on the SOLO2 trial for The ASCO Post was Don S. Dizon, MD, FACP, FASCO, Director of Women’s Cancers at Lifespan Cancer Institute and Professor of Medicine at Brown University, Providence, Rhode Island. “It’s great to get an overall survival advantage from a PARP inhibitor study. Coming...
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer
For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...
Study Finds Cancer-Related Deaths Declined in States With Expanded Access to Medicaid
States that adopted Medicaid expansion after passage of the Affordable Care Act (ACA) in 2010 saw a decline in cancer mortality rates by 29% compared with 25% in states that did not expand access to Medicaid, according to a study by Anna Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, New...
Cancer vs COVID-19: Clinical Trial Research During the Pandemic
The COVID-19 pandemic transformed cancer care, seemingly overnight, as practices scrambled to ensure a safe environment for caregivers and patients. Although regulatory burdens have been relaxed to allow patients to continue on trial treatment and telemedicine has expanded its competency and reach, ...
How the Lung Cancer Community Came Together During the COVID-19 Pandemic
The COVID-19 pandemic (caused by infection with the SARS-CoV-2 coronavirus) has created a host of diagnostic, treatment, and follow-up problems for patients with cancer of all types, and this is particularly true for patients with lung cancer, their families, and providers. Everyone wanted to...
Spartalizumab for Locally Advanced or Metastatic Anaplastic Thyroid Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Jaume Capdevila, MD, and colleagues found that the programmed cell death protein 1 (PD-1) inhibitor spartalizumab produced responses in a cohort of patients with locally advanced or metastatic anaplastic thyroid carcinoma, with all...
Byoung Chul Cho, MD, PhD, on NSCLC: Genetic Mutations and Immunotherapy vs Chemotherapy in KEYNOTE-042
Byoung Chul Cho, MD, PhD, of Yonsei Cancer Center and Severance Hospital, discusses the STK11 and KEAP1 mutations in non–small cell lung cancers, and their relationship to the efficacy of pembrolizumab monotherapy vs platinum-based chemotherapy as first-line treatment for PD-L1–positive advanced...
Highlights From the AACR Virtual Annual Meeting
This week, we’ll be featuring some research highlights from the AACR Virtual Annual Meeting, including data on a triplet regimen for women with high-risk, HER2-negative breast cancer; findings on immunotherapy combined with targeted therapy for patients with BRAF V600-mutated melanoma; and a paper...
Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.
Expert Point of View: Charles L. Sawyers, MD
Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center, New York, commented on the SWOG S1320 study presented at the 2020 American Association for Cancer Research Virtual Annual Meeting. “Intermittent therapy is standard with chemotherapy due to toxicity, but targeted therapies...
